112 related articles for article (PubMed ID: 12719749)
41. [Metastatic renal cell carcinoma: pretherapeutic approach before antiangiogenic treatment. A case report].
Méjean A; Guy L; Jacqmin D; Joly F; Négrier S; Pignot G
Prog Urol; 2010 Mar; 20 Suppl 1():S16-9. PubMed ID: 20493437
[TBL] [Abstract][Full Text] [Related]
42. [Neocarzinostatin therapy of advanced renal cell carcinoma].
Tari K; Satake I; Kojima S; Tsujii T; Yonese J
Gan To Kagaku Ryoho; 1988 Sep; 15(9):2719-23. PubMed ID: 2970825
[TBL] [Abstract][Full Text] [Related]
43. The changing natural history of renal cell carcinoma.
Pantuck AJ; Zisman A; Belldegrun AS
J Urol; 2001 Nov; 166(5):1611-23. PubMed ID: 11586189
[TBL] [Abstract][Full Text] [Related]
44. Current and future systemic treatments for renal cell carcinoma.
Fisher R; Gore M; Larkin J
Semin Cancer Biol; 2013 Feb; 23(1):38-45. PubMed ID: 22705280
[TBL] [Abstract][Full Text] [Related]
45. [A case of renal cell carcinoma with lung metastasis and local recurrence effectively treated with nephrectomy and UFT].
Taguchi H; Takaoka K; Matsuda M
Gan To Kagaku Ryoho; 1992 Dec; 19(14):2395-8. PubMed ID: 1463346
[TBL] [Abstract][Full Text] [Related]
46. Reconsidering the necessity of ipsilateral adrenalectomy during radical nephrectomy for renal cell carcinoma.
Leibovitch I; Raviv G; Mor Y; Nativ O; Goldwasser B
Urology; 1995 Sep; 46(3):316-20. PubMed ID: 7660505
[TBL] [Abstract][Full Text] [Related]
47. Cytoreductive nephrectomy in metastatic renal cell carcinoma.
Healy KA; Marshall FF; Ogan K
Expert Rev Anticancer Ther; 2006 Aug; 6(8):1295-304. PubMed ID: 16925495
[TBL] [Abstract][Full Text] [Related]
48. Everolimus in the treatment of renal cell carcinoma and neuroendocrine tumors.
Chan HY; Grossman AB; Bukowski RM
Adv Ther; 2010 Aug; 27(8):495-511. PubMed ID: 20623346
[TBL] [Abstract][Full Text] [Related]
49. Predicting cancer-control outcomes in patients with renal cell carcinoma.
Karakiewicz PI; Hutterer GC
Curr Opin Urol; 2007 Sep; 17(5):295-302. PubMed ID: 17762620
[TBL] [Abstract][Full Text] [Related]
50. Lenalidomide therapy for metastatic renal cell carcinoma.
Amato RJ; Hernandez-McClain J; Saxena S; Khan M
Am J Clin Oncol; 2008 Jun; 31(3):244-9. PubMed ID: 18525302
[TBL] [Abstract][Full Text] [Related]
51. Renal cell carcinoma with retroperitoneal lymph nodes: role of lymph node dissection.
Pantuck AJ; Zisman A; Dorey F; Chao DH; Han KR; Said J; Gitlitz BJ; Figlin RA; Belldegrun AS
J Urol; 2003 Jun; 169(6):2076-83. PubMed ID: 12771723
[TBL] [Abstract][Full Text] [Related]
52. [Clear cell renal carcinoma in children. Study of two cases and review of the literature].
Walter P; Vetter JM
Ann Pediatr (Paris); 1976 Sep; 23(8-9):541-50. PubMed ID: 16104190
[No Abstract] [Full Text] [Related]
53. The role of cytoreductive nephrectomy in the era of molecular targeted therapy.
Polcari AJ; Gorbonos A; Milner JE; Flanigan RC
Int J Urol; 2009 Mar; 16(3):227-33. PubMed ID: 19207114
[TBL] [Abstract][Full Text] [Related]
54. Continuing response to subsequent treatment lines with tyrosine kinase inhibitors in an adolescent with metastatic renal cell carcinoma.
De Pasquale MD; Pessolano R; Boldrini R; Ilari I; Donfrancesco A; Cortesi E; Jenkner A
J Pediatr Hematol Oncol; 2011 Jul; 33(5):e176-9. PubMed ID: 21552143
[TBL] [Abstract][Full Text] [Related]
55. [The medical treatment of renal cancer in adults].
Sculier JP
Rev Med Brux; 1989 May; 10(5):190-6. PubMed ID: 2662317
[TBL] [Abstract][Full Text] [Related]
56. Combination therapy of interleukin-2 and sorafenib improves survival benefits and prevents spontaneous pulmonary metastasis in murine renal cell carcinoma models.
Amagai Y; Matsumoto M; Hojo K; Iguchi M; Wada T; Tanaka H; Ide N; Kato A; Shichijo M; Abe K
Jpn J Clin Oncol; 2010 Jun; 40(6):503-7. PubMed ID: 20106881
[TBL] [Abstract][Full Text] [Related]
57. Radiation therapy in the treatment of metastatic renal-cell carcinoma.
Cutuli BF; Methlin A; Teissier E; Schumacher C; Jung GM
Prog Clin Biol Res; 1990; 348():179-86. PubMed ID: 1696735
[No Abstract] [Full Text] [Related]
58. The value of cytoreductive nephrectomy for metastatic renal cell carcinoma in the era of targeted therapy.
You D; Jeong IG; Ahn JH; Lee DH; Lee JL; Hong JH; Ahn H; Kim CS
J Urol; 2011 Jan; 185(1):54-9. PubMed ID: 21074811
[TBL] [Abstract][Full Text] [Related]
59. A phase II study of thalidomide in advanced metastatic renal cell carcinoma.
Minor DR; Monroe D; Damico LA; Meng G; Suryadevara U; Elias L
Invest New Drugs; 2002 Nov; 20(4):389-93. PubMed ID: 12448656
[TBL] [Abstract][Full Text] [Related]
60. The outcome of targeted therapies in patients with poor prognosis metastatic renal cell carcinoma.
Giuliani J; Marzola M
Cancer Biother Radiopharm; 2014 Sep; 29(7):298-300. PubMed ID: 24984202
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
